| Not Yet Recruiting | ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma NCT07021989 | Michael Spinner, MD | Phase 2 |
| Recruiting | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced T NCT06487624 | FBD Biologics Limited | Phase 1 |
| Recruiting | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL NCT06484920 | Rita Assi | Phase 2 |
| Recruiting | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma NCT05595447 | Hospital Regional de Alta Especialidad del Bajio | Phase 2 / Phase 3 |
| Unknown | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Cla NCT05137886 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatmen NCT04871607 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL NCT04938232 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT NCT04776265 | Grupo Argentino de Tratamiento de la Leucemia Aguda | — |
| Active Not Recruiting | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neop NCT04640779 | Mayo Clinic | Phase 1 |
| Completed | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606 | City of Hope Medical Center | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem NCT03259503 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Ref NCT04052997 | ADC Therapeutics S.A. | Phase 2 |
| Active Not Recruiting | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma NCT04134325 | UNC Lineberger Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma NCT03730363 | Reinhold Munker | Phase 1 |
| Completed | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT03739619 | Emory University | Phase 1 / Phase 2 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractor NCT03013933 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory NCT03016871 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgki NCT03057795 | City of Hope Medical Center | Phase 2 |
| Completed | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant NCT02869633 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02744612 | City of Hope Medical Center | Phase 2 |
| Completed | Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT02824029 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02254239 | Mayo Clinic | Phase 1 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Terminated | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma NCT02456675 | Incyte Corporation | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory H NCT02227199 | University of Washington | Phase 1 / Phase 2 |
| Completed | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients NCT01921387 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma NCT01703949 | University of Washington | Phase 2 |
| Completed | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients Wi NCT01701986 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma NCT01393717 | City of Hope Medical Center | Phase 2 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed NCT00860171 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |